Renal cell carcinoma treatment
Renal cell carcinoma treatment is a research topic within Pulmonary and Respiratory Medicine. Science Explorer counts 36k research works in it since 1950. 14.9% of them reached the world's top 10% most cited for their field and year.
This cluster of papers represents a comprehensive exploration of advancements in the research and treatment of renal cell carcinoma, including studies on various treatment modalities, prognostic factors, molecular characterization, nephron-sparing surgery, immunotherapy, genetic mutations, and clinical guidelines.
- Renal Cell Carcinoma
- Metastatic
- Treatment
- Therapy
- Prognostic Factors
- Molecular Characterization
- Nephron-Sparing Surgery
- Immunotherapy
- Genetic Mutations
- Clinical Guidelines
- Research works
- 36k fractional, since 1950
- In the world top 10%
- 5.4k per year above
- Top-10% rate
- 14.9% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +23% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Renal cell carcinoma treatment research?
By volume, the United States and China publish the most (1.7k and 1.6k works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.7k works
- 2 China 1.6k works
- 3 Japan 516 works
- 4 Italy 388 works
- 5 India 298 works
- 6 Germany 280 works
- 7 United Kingdom 246 works
- 8 France 237 works
- 9 South Korea 161 works
- 10 Spain 152 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Renal cell carcinoma treatment research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Renal cell carcinoma treatment research, followed by Memorial Sloan Kettering Cancer Center and Chinese Academy of Medical Sciences & Peking Union Medical College.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer CenterUnited States 54 works
- 2 Memorial Sloan Kettering Cancer CenterUnited States 43 works
- 3 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 34 works
- 4 The University of Texas Southwestern Medical CenterUnited States 32 works
- 5 Sichuan UniversityChina 31 works
- 6 Sun Yat-sen UniversityChina 28 works
- 7 Peking UniversityChina 28 works
- 8 Dana-Farber Cancer InstituteUnited States 28 works
- 9 Cleveland ClinicUnited States 27 works
- 10 Istituti di Ricovero e Cura a Carattere ScientificoItaly 27 works
Who are the leading researchers in Renal cell carcinoma treatment?
The most-cited researchers publishing on Renal cell carcinoma treatment include Steve Horvath and Jean‐Luc Raoul.
- 1 Steve Horvath United States 4.2k citations
- 2 Jean‐Luc Raoul France 3.5k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Renal cell carcinoma treatment research done?
The largest centres of Renal cell carcinoma treatment research in 2022–2025 are Beijing (China), Shanghai (China), Tokyo (Japan) and Guangzhou (China).
Largest cities, 2022–2025
Where is the best place to study Renal cell carcinoma treatment?
Among universities, judged by research, University of Bari Aldo Moro, Vita-Salute San Raffaele University and Icahn School of Medicine at Mount Sinai score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | University of Bari Aldo MoroItaly | 56.2 | 37.8% | 4.9× | 11 | +78.6% |
| 2 | Vita-Salute San Raffaele UniversityItaly | 52.3 | 14.6% | 15.3× | 14 | +3.7% |
| 3 | Icahn School of Medicine at Mount SinaiUnited States | 51.2 | 24.2% | 4.8× | 16 | +127.4% |
| 4 | Second Military Medical UniversityChina | 49.2 | 23.7% | 12.9× | 10 | -7.6% |
| 5 | Nanjing Medical UniversityChina | 47.4 | 21.5% | 5.9× | 21 | +55.1% |
| 6 | Harvard UniversityUnited States | 47.0 | 24.2% | 2.6× | 23 | +27.4% |
| 7 | University of VeronaItaly | 47.0 | 17.2% | 7.0× | 11 | +81.5% |
| 8 | Medical University of ViennaAustria | 46.0 | 24.1% | 5.9× | 12 | -41.2% |
| 9 | Dalian Medical UniversityChina | 46.0 | 17.5% | 8.5× | 11 | +85.1% |
| 10 | University of FlorenceItaly | 44.9 | 33.2% | 3.5× | 13 | -11.6% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Renal cell carcinoma treatment research growing?
Output in 2018–2022 was 23% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Renal cell carcinoma treatment.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.